Platelet Aggregation Onhibitors
Conditions
Keywords
antiplatelets, percutanous coronary intervention, acute coronary syndromes, laboratory efficacy
Brief summary
The ongoing LAPCOR (Laboratory AntiPlatelet efficacy and Clinical Outcome Registry) registry was initiated in 2008 at a tertiary care cardiac center, and consecutive patients, who underwent intracoronary stent implantation, have been included regardless of whether percutaneous coronary intervention (PCI) was performed on urgent or elective basis.Patients were included in the registry after having signed an informed consent for participation. No exclusion criterion has been applied for the registry participation. Efficacy of P2Y12 receptor antagonists has been measured by quantitative flow cytometric analysis of vasodilator-stimulated phosphoprotein (VASP) phosphorylation according to the manufacturer protocol (Platelet VASP; Diagnostica Stago, Biocytex, Asnières, France) on a FACScan flow cytometer (Becton Dickinson). Occurrence of major adverse cardiac events at 30 days, 6-months and one year follow up has been investigated.
Interventions
DRUGantiplatelet drugs - P2Y12 antagonists
Sponsors
Faculty Hospital Kralovske Vinohrady
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients after stent PCI treated with P2Y12 antagonist * Written informed consent
Exclusion criteria
\- None
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| laboratory efficacy of antiplatelet drugs measured as residual platelet reactivity, incidence of major adverse cardiovascular events and bleeding complications | During the 12 months after implantation of an intracoronary stent |
Countries
Czechia
Outcome results
None listed